Deep brain stimulation explained

Deep brain stimulation
Specialty:Neurosurgery

Deep brain stimulation (DBS) is a surgical procedure that implants a neurostimulator and electrodes which sends electrical impulses to specified targets in the brain responsible for movement control. The treatment is designed for a range of movement disorders such as Parkinson's disease, essential tremor, and dystonia, as well as for certain neuropsychiatric conditions like obsessive-compulsive disorder (OCD) and epilepsy.[1] The exact mechanisms of DBS are complex and not entirely clear, but it is known to modify brain activity in a structured way.[2]

DBS has been approved by the Food and Drug Administration as a treatment for essential tremor and Parkinson's disease (PD) since 1997.[3] DBS was approved for dystonia in 2003,[4] obsessive–compulsive disorder (OCD) in 2009, and epilepsy in 2018.[5] [6] [7] DBS has been studied in clinical trials as a potential treatment for chronic pain, for various affective disorders, including major depression, for Alzheimer's Disease and drug addiction, among other brain disorders. It is one of few neurosurgical procedures that allow blinded studies.[1]

As a first approximation, DBS is thought to mimic the clinical effects of lesioning[8], likely by attenuating (pathologically elevated) information flow through affected brain networks[9] . Thus, DBS is thought to create an 'informational lesion'[10], which can be switched off by turning off the DBS device, i.e. is reversible. This is a strong advantage compared to actual brain lesions that are at times also surgically applied to similar targets in similar conditions and which are permanent.

Medical use

Parkinson's disease

DBS is used to manage some of the symptoms of Parkinson's disease that cannot be adequately controlled with medications.[11] PD is treated by applying high-frequency (> 100 Hz) stimulation to target structures in the depth of the brain. Frequently used targets include the subthalamic nucleus (STN), internal pallidum (GPi) and ventrointermediate nucleus of the thalamus (VIM). The pedunculopontine nucleus has been used as an investigational target to treat freezing of gait.

DBS is recommended for people who have PD with motor fluctuations and tremors inadequately controlled by medication, or to those who are intolerant to medication, as long as they do not have severe neuropsychiatric problems.[12] Four areas of the brain have been treated with neural stimulators in PD. Most DBS surgeries in routine practice target either the GPi or the STN, which, in prospective trials have been equally efficient in reducing motor symptoms[13] [14], likely due to a shared network being stimulated with either target[15] . General differences between targets are not easy to summarize, but often include the following:

Selection of the correct DBS target is a complicated process. Multiple clinical characteristics are used to select the target including – identifying the most troublesome symptoms, the dose of levodopa that the patient is currently taking, the effects and side-effects of current medications and concurrent problems. Decisions are often made in multidisciplinary teams at specialized institutions.

Effectiveness

Generally, DBS is associated with a 30–60% improvement in motor score evaluations.[16] However, DBS is administered continuously and with fixed parameters and does not fully control motor fluctuations that characterize Parkinson's disease. Therefore, in recent years, the concept of Adaptive Deep Brain Stimulation (aDBS), a type of DBS that automatically adapts stimulation parameters to Parkinsonian symptoms, was developed. aDBS devices are currently under investigation to be adopted in clinical practice.[17]

Tourette syndrome

DBS has been used experimentally in treating adults with severe Tourette syndrome who do not respond to conventional treatment. Despite widely publicized early successes, DBS remains a highly experimental procedure for treating Tourette's, and more study is needed to determine whether long-term benefits outweigh the risks.[18] [19] [20] [21] The procedure is well tolerated, but complications include "short battery life, abrupt symptom worsening upon cessation of stimulation, hypomanic or manic conversion, and the significant time and effort involved in optimizing stimulation parameters".[22]

The procedure is invasive and expensive and requires long-term expert care. Benefits for severe Tourette's are inconclusive, considering the less robust effects of this surgery seen in the Netherlands. Tourette's is more common in pediatric populations, tending to remit in adulthood, so, in general, this would not be a recommended procedure for use on children. It may not always be obvious how to utilize DBS for a particular person because the diagnosis of Tourette's is based on a history of symptoms rather than an examination of neurological activity. Due to concern over the use of DBS in Tourette syndrome treatment, the Tourette Association of America convened a group of experts to develop recommendations guiding the use and potential clinical trials of DBS for TS.[23]

Robertson reported that DBS had been used on 55 adults by 2011, remained an experimental treatment at that time, and recommended that the procedure "should only be conducted by experienced functional neurosurgeons operating in centres which also have a dedicated Tourette syndrome clinic".[19] According to Malone et al. (2006), "Only patients with severe, debilitating, and treatment-refractory illness should be considered; while those with severe personality disorders and substance-abuse problems should be excluded."[22] Du et al. (2010) say, "As an invasive therapy, DBS is currently only advisable for severely affected, treatment-refractory TS adults".[20] Singer (2011) says, "pending determination of patient selection criteria and the outcome of carefully controlled clinical trials, a cautious approach is recommended".[18] Viswanathan et al. (2012) say DBS should be used for people with "severe functional impairment that cannot be managed medically".[24]

Epilepsy

As many as 36.3% of epilepsy patients are drug-resistant.[25] These patients are at risk for significant morbidity and mortality.[26] In cases where surgery is not an option, neurostimulation such as DBS, as well as vagus nerve stimulation and responsive neurostimulation can be considered. Targets other than the anterior nucleus of the thalamus have been studied for the treatment of epilepsy, such as the centromedian nucleus of the thalamus, the cerebellum and others.[27]

Adverse effects

DBS carries the risks of major surgery, with a complication rate related to the experience of the surgical team. The major complications include hemorrhage (1–2%) and infection (3–5%).[28]

The potential exists for neuropsychiatric side effects after DBS, including apathy, hallucinations, hypersexuality, cognitive dysfunction, depression, and euphoria. However, these effects may be temporary and related to (1) incorrect placement of electrodes, (2) open-loop VS closed-loop stimulation, meaning a constant stimulation or an A.I. monitoring delivery system[29] and (3) calibration of the stimulator, so these side effects are potentially reversible.[30]

Because the brain can shift slightly during surgery, the electrodes can become displaced or dislodged from the specific location. This may cause more profound complications such as personality changes, but electrode misplacement is relatively easy to identify using CT scan. Also, surgery complications may occur, such as bleeding within the brain. After surgery, swelling of the brain tissue, mild disorientation, and sleepiness are normal. After 2–4 weeks, a follow-up visit is used to remove sutures, turn on the neurostimulator, and program it.

Impaired swimming skills surfaced as an unexpected risk of the procedure; several Parkinson's disease patients lost their ability to swim after receiving deep brain stimulation.[31] [32]

Mechanisms

The exact mechanism of action of DBS is not known.[33] A variety of hypotheses try to explain the mechanisms of DBS:[34] [35]

  1. Depolarization blockade: Electrical currents block the neuronal output at or near the electrode site.
  2. Synaptic inhibition: This causes an indirect regulation of the neuronal output by activating axon terminals with synaptic connections to neurons near the stimulating electrode.
  3. Desynchronization of abnormal oscillatory activity of neurons
  4. Antidromic activation either activating/blockading distant neurons or blockading slow axons[2]

DBS represents an advance on previous treatments which involved pallidotomy (i.e., surgical ablation of the globus pallidus) or thalamotomy (i.e., surgical ablation of the thalamus).[36] Instead, a thin lead with multiple electrodes is implanted in the globus pallidus, nucleus ventralis intermedius thalami, or subthalamic nucleus, and electric pulses are used therapeutically. The lead from the implant is extended to the neurostimulator under the skin in the chest area.

Its direct effect on the physiology of brain cells and neurotransmitters is currently debated, but by sending high-frequency electrical impulses into specific areas of the brain, it can mitigate symptoms[37] and directly diminish the side effects induced by PD medications,[38] allowing a decrease in medications, or making a medication regimen more tolerable.

Components and placement

The DBS system consists of three components: the implanted pulse generator (IPG), the lead, and an extension. The IPG is a battery-powered neurostimulator encased in a titanium housing, which sends electrical pulses to the brain that interfere with neural activity at the target site. The lead is a coiled wire insulated in polyurethane with four platinum-iridium electrodes and is placed in one or two different nuclei of the brain. The lead is connected to the IPG by an extension, an insulated wire that runs below the skin, from the head, down the side of the neck, behind the ear, to the IPG, which is placed subcutaneously below the clavicle, or in some cases, the abdomen.[39] The IPG can be calibrated by a neurologist, nurse, or trained technician to optimize symptom suppression and control side effects.[40]

DBS leads are placed in the brain according to the type of symptoms to be addressed. For non-Parkinsonian essential tremor, the lead is placed in either the ventrointermediate nucleus of the thalamus or the zona incerta;[41] for dystonia and symptoms associated with PD (rigidity, bradykinesia/akinesia, and tremor), the lead may be placed in either the globus pallidus internus or the subthalamic nucleus; for OCD and depression to the nucleus accumbens; for incessant pain to the posterior thalamic region or periaqueductal gray; and for epilepsy treatment to the anterior thalamic nucleus.

All three components are surgically implanted inside the body. Lead implantation may take place under local anesthesia or under general anesthesia ("asleep DBS"), such as for dystonia. A hole about 14 mm in diameter is drilled in the skull and the probe electrode is inserted stereotactically, using either frame-based or frameless stereotaxis.[42] During the awake procedure with local anesthesia, feedback from the person is used to determine the optimal placement of the permanent electrode. During the asleep procedure, intraoperative MRI guidance is used for direct visualization of brain tissue and device.[43] The installation of the IPG and extension leads occurs under general anesthesia.[44] The right side of the brain is stimulated to address symptoms on the left side of the body and vice versa.

Research

Chronic pain

Stimulation of the periaqueductal gray and periventricular gray for nociceptive pain, and the internal capsule, ventral posterolateral nucleus, and ventral posteromedial nucleus for neuropathic pain has produced impressive results with some people, but results vary. One study[45] of 17 people with intractable cancer pain found that 13 were virtually pain-free and only four required opioid analgesics on release from hospital after the intervention. Most ultimately did resort to opioids, usually in the last few weeks of life.[46] DBS has also been applied for phantom limb pain.[47]

Major depression and obsessive-compulsive disorder

DBS has been used in a small number of clinical trials to treat people with severe treatment-resistant depression (TRD).[48] A number of neuroanatomical targets have been used for DBS for TRD including the subgenual cingulate gyrus, posterior gyrus rectus,[49] nucleus accumbens,[50] ventral capsule/ventral striatum, inferior thalamic peduncle, and the lateral habenula.[48] A recently proposed target of DBS intervention in depression is the superolateral branch of the medial forebrain bundle; its stimulation lead to surprisingly rapid antidepressant effects.[51]

The small numbers in the early trials of DBS for TRD currently limit the selection of an optimal neuroanatomical target.[48] Evidence is insufficient to support DBS as a therapeutic modality for depression; however, the procedure may be an effective treatment modality in the future.[52] In fact, beneficial results have been documented in the neurosurgical literature, including a few instances in which people who were deeply depressed were provided with portable stimulators for self-treatment.[53] [54] [55]

A systematic review of DBS for TRD and OCD identified 23 cases, nine for OCD, seven for TRD, and one for both. "[A]bout half the patients did show dramatic improvement" and adverse events were "generally trivial" given the younger age of the psychiatric population relative to the age of people with movement disorders.[56] The first randomized, controlled study of DBS for the treatment of TRD targeting the ventral capsule/ventral striatum area did not demonstrate a significant difference in response rates between the active and sham groups at the end of a 16-week study.[57] However, a second randomized controlled study of ventral capsule DBS for TRD did demonstrate a significant difference in response rates between active DBS (44% responders) and sham DBS (0% responders).[58] Efficacy of DBS is established for OCD, with on average 60% responders in severely ill and treatment-resistant patients.[59] Based on these results the Food and Drug Administration (FDA) has approved DBS for treatment-resistant OCD under a Humanitarian Device Exemption (HDE), requiring that the procedure be performed only in a hospital with specialist qualifications to do so.

DBS for TRD can be as effective as antidepressants and have good response and remission rates, but adverse effects and safety must be more fully evaluated. Common side effects include "wound infection, perioperative headache, and worsening/irritable mood [and] increased suicidality".[60]

Other clinical applications

Results of DBS in people with dystonia, where positive effects often appear gradually over a period of weeks to months, indicate a role of functional reorganization in at least some cases.[61] The procedure has been tested for effectiveness in people with epilepsy that is resistant to medication.[62] DBS may reduce or eliminate epileptic seizures with programmed or responsive stimulation.

DBS of the septal areas of persons with schizophrenia has resulted in enhanced alertness, cooperation, and euphoria.[63] Persons with narcolepsy and complex-partial seizures also reported euphoria and sexual thoughts from self-elicited DBS of the septal nuclei.

Orgasmic ecstasy was reported with the electrical stimulation of the brain with depth electrodes in the left hippocampus at 3mA, and the right hippocampus at 1 mA.[64]

In 2015, a group of Brazilian researchers led by neurosurgeon described a new technique that allows for simultaneous implants of electrodes called bilateral stereotactic procedure for DBS. The main benefits are less time spent on the procedure and greater accuracy.[65]

In 2016, DBS was found to improve learning and memory in a mouse model of Rett syndrome.[66] More recent (2018) work showed, that forniceal DBS upregulates genes involved in synaptic function, cell survival, and neurogenesis,[67] making some first steps at explaining the restoration of hippocampal circuit function.

Epilepsy target

According to one long-term follow-up study, DBS targeting the anterior nucleus of the thalamus may be somewhat more effective for temporal lobe epilepsy, and efficacy may increase over time.[68] [69]

See also

Further reading

External links

Notes and References

  1. Kringelbach ML, Jenkinson N, Owen SL, Aziz TZ . Translational principles of deep brain stimulation . Nature Reviews. Neuroscience . 8 . 8 . 623–635 . August 2007 . 17637800 . 10.1038/nrn2196 . 147427108 .
  2. García MR, Pearlmutter BA, Wellstead PE, Middleton RH . A slow axon antidromic blockade hypothesis for tremor reduction via deep brain stimulation . PLOS ONE . 8 . 9 . e73456 . 16 September 2013 . 24066049 . 3774723 . 10.1371/journal.pone.0073456 . free . 2013PLoSO...873456G .
  3. Web site: FDA approves brain implant to help reduce Parkinson's disease and essential tremor symptoms. FDA. May 23, 2016. The first device, Medtronic's Activa Deep Brain Stimulation Therapy System, was approved in 1997 for tremor associated with essential tremor and Parkinson's disease..
  4. News: Phillips S . 'Brain pacemaker' for a rare disorder . https://web.archive.org/web/20210428014405/https://www.nbcnews.com/id/wbna19265007 . dead . April 28, 2021 . NBC News . 17 June 2007 .
  5. Medtronic Receives FDA Approval for Deep Brain Stimulation Therapy for Medically Refractory Epilepsy . Medtronic . 1 May 2018 .
  6. Web site: FDA Approves Humanitarian Device Exemption for Deep Brain Stimulator for Severe Obsessive-Compulsive Disorder. FDA.
  7. Gildenberg PL . Evolution of neuromodulation . Stereotactic and Functional Neurosurgery . 83 . 2–3 . 71–79 . 2005 . 16006778 . 10.1159/000086865 . 20234898 .
  8. Book: Parkinson's Disease and Related Disorders, Part II . Morris JG, Owler B, Hely MA, Fung VS . 2007 . 978-0-444-52893-3 . Handbook of Clinical Neurology . 84 . 459–478 . Hydrocephalus and structural lesions . 10.1016/S0072-9752(07)84055-3 . 1132129865 . 18808964.
  9. Hollunder . Barbara . Ostrem . Jill L. . Sahin . Ilkem Aysu . Rajamani . Nanditha . Oxenford . Simón . Butenko . Konstantin . Neudorfer . Clemens . Reinhardt . Pablo . Zvarova . Patricia . Polosan . Mircea . Akram . Harith . Vissani . Matteo . Zhang . Chencheng . Sun . Bomin . Navratil . Pavel . March 2024 . Mapping dysfunctional circuits in the frontal cortex using deep brain stimulation . Nature Neuroscience . en . 27 . 3 . 573–586 . 10.1038/s41593-024-01570-1 . 1097-6256 . 10917675 . 38388734.
  10. Grill . Warren M. . Snyder . Andrea N. . Miocinovic . Svjetlana . May 2004 . Deep brain stimulation creates an informational lesion of the stimulated nucleus: . NeuroReport . en . 15 . 7 . 1137–1140 . 10.1097/00001756-200405190-00011 . 0959-4965.
  11. U.S. Department of Health and Human Services. FDA approves implanted brain stimulator to control tremors. Retrieved February 10, 2015.
  12. Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, Stefani A, Horak FB, Okun MS, Foote KD, Krack P, Pahwa R, Henderson JM, Hariz MI, Bakay RA, Rezai A, Marks WJ, Moro E, Vitek JL, Weaver FM, Gross RE, DeLong MR . 6 . Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues . Archives of Neurology . 68 . 2 . 165 . February 2011 . 20937936 . 4523130 . 10.1001/archneurol.2010.260 .
  13. Follett . Kenneth A. . Weaver . Frances M. . Stern . Matthew . Hur . Kwan . Harris . Crystal L. . Luo . Ping . Marks . William J. . Rothlind . Johannes . Sagher . Oren . Moy . Claudia . Pahwa . Rajesh . Burchiel . Kim . Hogarth . Penelope . Lai . Eugene C. . Duda . John E. . 2010-06-03 . Pallidal versus Subthalamic Deep-Brain Stimulation for Parkinson's Disease . New England Journal of Medicine . en . 362 . 22 . 2077–2091 . 10.1056/NEJMoa0907083 . 0028-4793.
  14. Odekerken . Vincent J.J. . Boel . Judith A. . Schmand . Ben A. . de Haan . Rob J. . Figee . M. . van den Munckhof . Pepijn . Schuurman . P. Richard . de Bie . Rob M.A. . For the NSTAPS study group . NSTAPS study group . de Bie . R.M.A. . Bour . L. . Contarino . M.F. . de Haan . R.J. . Iwan . M. . 2016-02-23 . GPi vs STN deep brain stimulation for Parkinson disease: Three-year follow-up . Neurology . en . 86 . 8 . 755–761 . 10.1212/WNL.0000000000002401 . 0028-3878.
  15. Sobesky . Leon . Goede . Lukas . Odekerken . Vincent J J . Wang . Qiang . Li . Ningfei . Neudorfer . Clemens . Rajamani . Nanditha . Al-Fatly . Bassam . Reich . Martin . Volkmann . Jens . de Bie . Rob M A . Kühn . Andrea A . Horn . Andreas . 2022-03-29 . Subthalamic and pallidal deep brain stimulation: are we modulating the same network? . Brain . en . 145 . 1 . 251–262 . 10.1093/brain/awab258 . 0006-8950.
  16. Book: Dallapiazza RF, De Vloo P, Fomenko A, Lee DJ, Hamani C, Munhoz RP, Hodaie M, Lozano AM, Fasano A, Kalia SK . 6 . 2018 . Considerations for Patient and Target Selection in Deep Brain Stimulation surgery for Parkinson's disease . Stoker TB, Greenland JC . Parkinson's disease: Pathogenesis and clinical aspects . 145–160 . Brisbane . Codon Publications . 978-0-9944381-6-4 . 10.15586/codonpublications.parkinsonsdisease.2018.ch8 . 30702838 . 81155324 .
  17. Guidetti M, Marceglia S, Loh A, Harmsen IE, Meoni S, Foffani G, Lozano AM, Moro E, Volkmann J, Priori A . 6 . Clinical perspectives of adaptive deep brain stimulation . Brain Stimulation . 14 . 5 . 1238–1247 . September 1, 2021 . 34371211 . 10.1016/j.brs.2021.07.063 . free . 236949013 . free . 2434/865610 .
  18. Book: 10.1016/B978-0-444-52014-2.00046-X . Tourette syndrome and other tic disorders . Hyperkinetic Movement Disorders . Handbook of Clinical Neurology . 2011 . Singer HS . 100 . 641–657 . 21496613 . 978-0-444-52014-2 . Also see Singer HS . Tourette's syndrome: from behaviour to biology . The Lancet. Neurology . 4 . 3 . 149–159 . March 2005 . 15721825 . 10.1016/S1474-4422(05)01012-4 . 20181150 .
  19. Robertson MM . Gilles de la Tourette syndrome: the complexities of phenotype and treatment . British Journal of Hospital Medicine . 72 . 2 . 100–107 . February 2011 . 21378617 . 10.12968/hmed.2011.72.2.100 .
  20. Du JC, Chiu TF, Lee KM, Wu HL, Yang YC, Hsu SY, Sun CS, Hwang B, Leckman JF . 6 . Tourette syndrome in children: an updated review . Pediatrics and Neonatology . 51 . 5 . 255–264 . October 2010 . 20951354 . 10.1016/S1875-9572(10)60050-2 . free .
  21. [Tourette Association of America|Tourette Syndrome Association]
  22. Book: Behavioral neurosurgery . 241–247 . . 16536372 . Walkup JT, Mink JW, Hollenbeck PJ . Tourette Syndrome . Advances in Neurology . 2006 . 99 . Lippincott Williams & Wilkins . 978-0-7817-9970-6 .
  23. Mink JW, Walkup J, Frey KA, Como P, Cath D, Delong MR, Erenberg G, Jankovic J, Juncos J, Leckman JF, Swerdlow N, Visser-Vandewalle V, Vitek JL . 6 . Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome . Movement Disorders . 21 . 11 . 1831–1838 . November 2006 . 16991144 . 10.1002/mds.21039 . free . Tourette Syndrome Association . 16353255 . 2027.42/55891 .
  24. Viswanathan A, Jimenez-Shahed J, Baizabal Carvallo JF, Jankovic J . Deep brain stimulation for Tourette syndrome: target selection . Stereotactic and Functional Neurosurgery . 90 . 4 . 213–224 . 2012 . 22699684 . 10.1159/000337776 . free .
  25. Sultana B, Panzini MA, Veilleux Carpentier A, Comtois J, Rioux B, Gore G, Bauer PR, Kwon CS, Jetté N, Josephson CB, Keezer MR . 6 . Incidence and Prevalence of Drug-Resistant Epilepsy: A Systematic Review and Meta-analysis . Neurology . 96 . 17 . 805–817 . April 2021 . 33722992 . 10.1212/WNL.0000000000011839 . free . 233401199 . 1866/26896 .
  26. Sperling MR . The consequences of uncontrolled epilepsy . CNS Spectrums . 9 . 2 . 98–101, 106–9 . February 2004 . 14999166 . 10.1017/s1092852900008464 . 32869839 .
  27. Li MC, Cook MJ . Deep brain stimulation for drug-resistant epilepsy . Epilepsia . 59 . 2 . 273–290 . February 2018 . 29218702 . 10.1111/epi.13964 . free . 23819562 . free . 11343/293997 .
  28. Doshi PK . Long-term surgical and hardware-related complications of deep brain stimulation . Stereotactic and Functional Neurosurgery . 89 . 2 . 89–95 . April 2011 . 21293168 . 10.1159/000323372 . 10553177 .
  29. Scangos KW, Makhoul GS, Sugrue LP, Chang EF, Krystal AD . State-dependent responses to intracranial brain stimulation in a patient with depression . Nature Medicine . 27 . 2 . 229–231 . February 2021 . 33462446 . 8284979 . 10.1038/s41591-020-01175-8 .
  30. Burn DJ, Tröster AI . Neuropsychiatric complications of medical and surgical therapies for Parkinson's disease . Journal of Geriatric Psychiatry and Neurology . 17 . 3 . 172–180 . September 2004 . 15312281 . 10.1177/0891988704267466 . 441486 .
  31. News: George J . Deep Brain Stimulation May Put Parkinson's Patients at Risk for Drowning . MedPage Today . 27 November 2019 .
  32. Bangash OK, Thorburn M, Garcia-Vega J, Walters S, Stell R, Starkstein SE, Lind CR . Drowning hazard with deep brain stimulation: case report . Journal of Neurosurgery . 124 . 5 . 1513–1516 . May 2016 . 26566200 . 10.3171/2015.5.JNS15589 . free .
  33. Book: Mogilner A.Y. . Benabid A.L. . Rezai A.R. . Chronic Therapeutic Brain Stimulation: History, Current Clinical Indications, and Future Prospects . Markov, Marko . Paul J. Rosch . Bioelectromagnetic medicine . Marcel Dekker . New York . 2004 . 133–151 . 978-0-8247-4700-8 .
  34. McIntyre CC, Thakor NV . Uncovering the mechanisms of deep brain stimulation for Parkinson's disease through functional imaging, neural recording, and neural modeling . Critical Reviews in Biomedical Engineering . 30 . 4–6 . 249–281 . 2002 . 12739751 . 10.1615/critrevbiomedeng.v30.i456.20 .
  35. Herrington TM, Cheng JJ, Eskandar EN . Mechanisms of deep brain stimulation . Journal of Neurophysiology . 115 . 1 . 19–38 . January 2016 . 26510756 . 4760496 . 10.1152/jn.00281.2015 .
  36. Machado A, Rezai AR, Kopell BH, Gross RE, Sharan AD, Benabid AL . Deep brain stimulation for Parkinson's disease: surgical technique and perioperative management . Movement Disorders . 21. Suppl 14 . S247–S258 . June 2006 . 16810722 . 10.1002/mds.20959 . 18194178 .
  37. Moro E, Lang AE . Criteria for deep-brain stimulation in Parkinson's disease: review and analysis . Expert Review of Neurotherapeutics . 6 . 11 . 1695–1705 . November 2006 . 17144783 . 10.1586/14737175.6.11.1695 . 20857769 .
  38. Apetauerova D, Ryan RK, Ro SI, Arle J, Shils J, Papavassiliou E, Tarsy D . End of day dyskinesia in advanced Parkinson's disease can be eliminated by bilateral subthalamic nucleus or globus pallidus deep brain stimulation . Movement Disorders . 21 . 8 . 1277–1279 . August 2006 . 16637040 . 10.1002/mds.20896 . 42122286 .
  39. Web site: Deep Brain Stimulation for Movement Disorders . National Institute on Neurological Disorders and Stroke .
  40. Volkmann J, Herzog J, Kopper F, Deuschl G . Introduction to the programming of deep brain stimulators . Movement Disorders . 17 . Suppl 3 . S181–S187 . 2002 . 11948775 . 10.1002/mds.10162 . 21988668 .
  41. Lee JY, Deogaonkar M, Rezai A . Deep brain stimulation of globus pallidus internus for dystonia . Parkinsonism & Related Disorders . 13 . 5 . 261–265 . July 2007 . 17081796 . 10.1016/j.parkreldis.2006.07.020 .
  42. Owen CM, Linskey ME . Frame-based stereotaxy in a frameless era: current capabilities, relative role, and the positive- and negative predictive values of blood through the needle . Journal of Neuro-Oncology . 93 . 1 . 139–149 . May 2009 . 19430891 . 10.1007/s11060-009-9871-y . free .
  43. Starr PA, Martin AJ, Ostrem JL, Talke P, Levesque N, Larson PS . Subthalamic nucleus deep brain stimulator placement using high-field interventional magnetic resonance imaging and a skull-mounted aiming device: technique and application accuracy . Journal of Neurosurgery . 112 . 3 . 479–490 . March 2010 . 19681683 . 2866526 . 10.3171/2009.6.JNS081161 .
  44. Web site: Deep Brain Stimulation for Movement Disorders . University of Pittsburgh .
  45. Young RF, Brechner T . Electrical stimulation of the brain for relief of intractable pain due to cancer . Cancer . 57 . 6 . 1266–1272 . March 1986 . 3484665 . 10.1002/1097-0142(19860315)57:6<1266::aid-cncr2820570634>3.0.co;2-q . 41929961 .
  46. Book: Johnson MI, Oxberry SG, Robb K . Stimulation-induced analgesia. 235–250. Sykes N, Bennett MI & Yuan C-S. Clinical pain management: Cancer pain. 2nd. 978-0-340-94007-5 . Hodder Arnold. London. 2008.
  47. Kringelbach ML, Jenkinson N, Green AL, Owen SL, Hansen PC, Cornelissen PL, Holliday IE, Stein J, Aziz TZ . 6 . Deep brain stimulation for chronic pain investigated with magnetoencephalography . NeuroReport . 18 . 3 . 223–228 . February 2007 . 17314661 . 10.1097/wnr.0b013e328010dc3d . 7091307 . 10.1.1.511.2667 .
  48. Anderson RJ, Frye MA, Abulseoud OA, Lee KH, McGillivray JA, Berk M, Tye SJ . Deep brain stimulation for treatment-resistant depression: efficacy, safety and mechanisms of action . Neuroscience and Biobehavioral Reviews . 36 . 8 . 1920–1933 . September 2012 . 22721950 . 10.1016/j.neubiorev.2012.06.001 . 207089716 .
  49. Accolla EA, Aust S, Merkl A, Schneider GH, Kühn AA, Bajbouj M, Draganski B . Deep brain stimulation of the posterior gyrus rectus region for treatment resistant depression . Journal of Affective Disorders . 194 . 33–37 . April 2016 . 26802505 . 10.1016/j.jad.2016.01.022 . 366972 . free .
  50. Schlaepfer TE, Cohen MX, Frick C, Kosel M, Brodesser D, Axmacher N, Joe AY, Kreft M, Lenartz D, Sturm V . 6 . Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression . Neuropsychopharmacology . 33 . 2 . 368–377 . January 2008 . 17429407 . 10.1038/sj.npp.1301408 . free .
  51. Schlaepfer TE, Bewernick BH, Kayser S, Mädler B, Coenen VA . Rapid effects of deep brain stimulation for treatment-resistant major depression . Biological Psychiatry . 73 . 12 . 1204–1212 . June 2013 . 23562618 . 10.1016/j.biopsych.2013.01.034 . 6374368 .
  52. Murphy DN, Boggio P, Fregni F . Transcranial direct current stimulation as a therapeutic tool for the treatment of major depression: insights from past and recent clinical studies . Current Opinion in Psychiatry . 22 . 3 . 306–311 . May 2009 . 19339889 . 10.1097/YCO.0b013e32832a133f . 11392351 .
  53. Book: Delgado J . Physical Control of the Mind: Toward a Psychocivilized Society. 1986. Harper and Row. New York . 0-06-131914-7.
  54. Faria MA . Violence, mental illness, and the brain - A brief history of psychosurgery: Part 3 - From deep brain stimulation to amygdalotomy for violent behavior, seizures, and pathological aggression in humans . Surgical Neurology International . 4 . 1 . 91 . 2013 . 23956934 . 3740620 . 10.4103/2152-7806.115162 . free .
  55. Robison RA, Taghva A, Liu CY, Apuzzo ML . Surgery of the mind, mood, and conscious state: an idea in evolution . World Neurosurgery . 77 . 5–6 . 662–686 . 2012 . 22446082 . 10.1016/j.wneu.2012.03.005 .
  56. Lakhan SE, Callaway E . Deep brain stimulation for obsessive-compulsive disorder and treatment-resistant depression: systematic review . BMC Research Notes . 3 . 1 . 60 . March 2010 . 20202203 . 2838907 . 10.1186/1756-0500-3-60 . free .
  57. Dougherty DD, Rezai AR, Carpenter LL, Howland RH, Bhati MT, O'Reardon JP, Eskandar EN, Baltuch GH, Machado AD, Kondziolka D, Cusin C, Evans KC, Price LH, Jacobs K, Pandya M, Denko T, Tyrka AR, Brelje T, Deckersbach T, Kubu C, Malone DA . 6 . A Randomized Sham-Controlled Trial of Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Chronic Treatment-Resistant Depression . Biological Psychiatry . 78 . 4 . 240–248 . August 2015 . 25726497 . 10.1016/j.biopsych.2014.11.023 . 22644265 .
  58. Bergfeld IO, Mantione M, Hoogendoorn ML, Ruhé HG, Notten P, van Laarhoven J, Visser I, Figee M, de Kwaasteniet BP, Horst F, Schene AH, van den Munckhof P, Beute G, Schuurman R, Denys D . 6 . Deep Brain Stimulation of the Ventral Anterior Limb of the Internal Capsule for Treatment-Resistant Depression: A Randomized Clinical Trial . JAMA Psychiatry . 73 . 5 . 456–464 . May 2016 . 27049915 . 10.1001/jamapsychiatry.2016.0152 . free .
  59. Alonso P, Cuadras D, Gabriëls L, Denys D, Goodman W, Greenberg BD, Jimenez-Ponce F, Kuhn J, Lenartz D, Mallet L, Nuttin B, Real E, Segalas C, Schuurman R, du Montcel ST, Menchon JM . 6 . Deep Brain Stimulation for Obsessive-Compulsive Disorder: A Meta-Analysis of Treatment Outcome and Predictors of Response . PLOS ONE . 10 . 7 . e0133591 . 2015-07-24 . 26208305 . 4514753 . 10.1371/journal.pone.0133591 . free . 2015PLoSO..1033591A .
  60. Moreines JL, McClintock SM, Holtzheimer PE . Neuropsychologic effects of neuromodulation techniques for treatment-resistant depression: a review . Brain Stimulation . 4 . 1 . 17–27 . January 2011 . 21255751 . 3023999 . 10.1016/j.brs.2010.01.005 .
  61. Krauss JK . Deep brain stimulation for dystonia in adults. Overview and developments . Stereotactic and Functional Neurosurgery . 78 . 3–4 . 168–182 . 2002 . 12652041 . 10.1159/000068963 . 71888143 .
  62. Wu C, Sharan AD . Neurostimulation for the treatment of epilepsy: a review of current surgical interventions . Neuromodulation . 16 . 1 . 10–24; discussion 24 . Jan–Feb 2013 . 22947069 . 10.1111/j.1525-1403.2012.00501.x . 1711587 .
  63. Heath RG . Pleasure and brain activity in man. Deep and surface electroencephalograms during orgasm . The Journal of Nervous and Mental Disease . 154 . 1 . 3–18 . January 1972 . 5007439 . 10.1097/00005053-197201000-00002 . 136706 .
  64. Surbeck W, Bouthillier A, Nguyen DK . Bilateral cortical representation of orgasmic ecstasy localized by depth electrodes . Epilepsy & Behavior Case Reports . 1 . 62–65 . 2013 . 25667829 . 4150648 . 10.1016/j.ebcr.2013.03.002 .
  65. Fonoff ET, Azevedo A, Angelos JS, Martinez RC, Navarro J, Reis PR, Sepulveda ME, Cury RG, Ghilardi MG, Teixeira MJ, Lopez WO . 6 . Simultaneous bilateral stereotactic procedure for deep brain stimulation implants: a significant step for reducing operation time . Journal of Neurosurgery . 125 . 1 . 85–89 . July 2016 . 26684776 . 10.3171/2015.7.JNS151026 . free .
  66. Lu H, Ash RT, He L, Kee SE, Wang W, Yu D, Hao S, Meng X, Ure K, Ito-Ishida A, Tang B, Sun Y, Ji D, Tang J, Arenkiel BR, Smirnakis SM, Zoghbi HY . 6 . Loss and Gain of MeCP2 Cause Similar Hippocampal Circuit Dysfunction that Is Rescued by Deep Brain Stimulation in a Rett Syndrome Mouse Model . Neuron . 91 . 4 . 739–747 . August 2016 . 27499081 . 5019177 . 10.1016/j.neuron.2016.07.018 .
  67. Pohodich AE, Yalamanchili H, Raman AT, Wan YW, Gundry M, Hao S, Jin H, Tang J, Liu Z, Zoghbi HY . 6 . Forniceal deep brain stimulation induces gene expression and splicing changes that promote neurogenesis and plasticity . eLife . 7 . March 2018 . 29570050 . 5906096 . 10.7554/elife.34031 . free .
  68. Razavi B, Rao VR, Lin C, Bujarski KA, Patra SE, Burdette DE, Geller EB, Brown MM, Johnson EA, Drees C, Chang EF, Greenwood JE, Heck CN, Jobst BC, Gwinn RP, Warner NM, Halpern CH . 6 . Real-world experience with direct brain-responsive neurostimulation for focal onset seizures . Epilepsia . 61 . 8 . 1749–1757 . August 2020 . 32658325 . 7496294 . 10.1111/epi.16593 .
  69. Chrastina J, Novák Z, Zeman T, Kočvarová J, Pail M, Doležalová I, Jarkovský J, Brázdil M . 6 . Single-center long-term results of vagus nerve stimulation for epilepsy: A 10-17 year follow-up study . Seizure . 59 . 41–47 . July 2018 . 29738985 . 10.1016/j.seizure.2018.04.022 . 13700901 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Deep brain stimulation".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.